Skip to content

MDTrials: what changed

BE 0822.234.455NACE 72.101, Research and development on biotechnologyOther company

Position among the sector peers

What moved

Only one financial year

Comparing needs two financial years with figures read. This company has one.

Value

latest balance sheet 30-09-2025 · indication, not a valuation or advice

Indicative value of the equity

Indication, not a valuation or advice
€381,741 to €461,540

Midpoint €414,991 · 50% capitalised earnings, 50% adjusted equity

Capitalisation rate 12% result over 3 years earnings weight 50%

Adjusted equity €364,489
Capitalised earnings €398,993 to €558,590
Indication €381,741 to €461,540

Adjusted equity

balance sheet 30-09-2025
Equity (10/15)
€364,489
Revaluation of assets
€0
Deferred tax on the revaluation
€0
Other adjustment
€0
Adjusted equity
€364,489

Capitalised earnings

net result for the year (9904)
2025
€55,859
Average result
€55,859
Divided by the capitalisation rate
14% / 12% / 10%
Capitalised earnings
€398,993 / €465,492 / €558,590

Limits of the indication

  • Checked holds no market prices or comparable transactions.
  • Anything after the latest accounts and items off the balance sheet (guarantees, leases, disputes) are left out.
  • Checked does not know the real value of buildings, stock and receivables. Enter your own revaluation or adjustment for it.
  • The owner's role in the business, synergies for a buyer and the tax consequences of a sale are left out.

For a valuation to base a decision on, go to a company auditor or a certified accountant.

Calculation and sources

Source: filed annual accounts (NBB) and main activity (KBO). The value is an indication, not a valuation or advice. Prepared on 10 November 2026 via checked.be.